Peptide guide

Wolverine

The community name for a blended vial of BPC-157 and TB-500, sold as a single soft-tissue recovery stack.

Wolverine is not its own peptide. It's a single vial holding two compounds at once, BPC-157 and TB-500, the two most-used recovery peptides, premixed so you draw both in one shot. The name is borrowed from the comic character who heals fast; it isn't a clinical term. Neither compound is FDA-approved, the evidence behind both is overwhelmingly from animals, and both are WADA-banned. People run them together because their reported strengths sit in different places: BPC-157 leans toward tendon, ligament, and gut tissue, TB-500 toward cell migration and flexibility. The practical questions are how to handle the blended vial and how not to get scammed buying it.

By the Zapify Research team

Reviewed against 10 clinical & research sources · Updated June 2026 · Educational use only

Type: BlendBPC-157 + TB-500
Route: Subcutaneous
Typical dose: ~250–500 mcg each/daydrawn together
Cycle: 6–12 wksthen off
Storage: Mixed: ~4 wksSealed: months
Status: Not FDA-approved

What is Wolverine?

Not a molecule but a marketing label for one vial of BPC-157 and TB-500 premixed, so you inject both recovery peptides in one shot.

Wolverine is a blend, not a molecule of its own. A single vial holds two separate peptides, BPC-157 and TB-500, premixed so one injection delivers both. The name comes from the comic-book character known for healing fast. It's a marketing label the recovery community settled on, not a clinical designation, and there's no "Wolverine peptide" sitting in a lab somewhere.

The two compounds inside it are the flagship recovery peptides, each with its own full guide. BPC-157 is a 15-amino-acid fragment first found in gastric juice, studied most in tendon, ligament, and gut tissue. TB-500 is a 7-amino-acid fragment of the protein thymosin beta-4, studied more for cell migration and flexibility. Running them as a stack is common enough that sellers started bottling them together to save the buyer from mixing two vials. Ratios vary between sellers, so check what's actually in the vial before you assume it's even.

Because Wolverine is just those two compounds in one bottle, it inherits everything true of each. The evidence, the caveats, the banned status, the sourcing risk all carry over from both. Read the BPC-157 and TB-500 guides alongside this one; nothing here replaces what's in them.

Neither BPC-157 nor TB-500 is FDA-approved, so the blend isn't either. Almost everything known about both comes from animal and cell-culture studies, and no published trial has tested the combination in humans. Treat it as two experimental research compounds in one vial, not a proven medicine.

What is it studied for?

No study has tested the blend itself; the evidence is two separate stacks of almost entirely animal and cell-culture work sitting side by side.

No study has tested the Wolverine blend itself. What exists is the separate research on each compound, almost all of it in animals and cell cultures. A 2025 systematic review of BPC-157 in orthopaedic sports medicine counted 35 preclinical studies and a single human one; the marketed TB-500 fragment has no completed human efficacy trials at all. So the combination's evidence base is two stacks of animal work sitting side by side, with nothing on the pair together.

Evidence base, by subject

DozensAnimal & lab studies (each compound)

NoneHuman trials of the blend

The case for combining them rests on the two compounds covering different parts of repair:

BPC-157: local repairTendons, ligaments, joints, and the gut lining. It appears to grow new blood vessels at an injury site and support the cells that lay down collagen. This is the local, structural half.

TB-500: cell migrationBy managing actin inside cells, thymosin beta-4 helps repair cells move toward a wound. The flexibility and whole-body recovery claims trace back here. This is the systemic half.

The stack logicBPC-157 builds the conditions for repair; TB-500 mobilizes the cells that do it. People run both hoping the local and systemic mechanisms add up rather than overlap.

Whether the two actually add up in a living body is untested. Each mechanism is reasonable on its own and partly characterized in the lab. There's no human data showing they combine, and a 2024 in-vitro study even found the TB-500 fragment may be less active than a metabolite it breaks down into. The synergy is the selling point, not a settled fact.

Why people use it

People run it for stubborn soft-tissue injuries and whole-body recovery in one shot, but no human trial shows the blend delivers any of it.

People reach for the blend instead of a single peptide when they want both mechanisms at once, and the convenience of one shot. These are the reasons they try it, not evidence that it delivers:

A stubborn soft-tissue injury that hasn't settled with rest and rehab, where they'd otherwise consider BPC-157 and TB-500 separately anyway.
Wanting broad, whole-body recovery rather than one specific joint, which is the usual argument for stacking the two.
Convenience: one vial and one injection instead of mixing and drawing from two.
The wear of hard, repeated training, and wanting to keep training through it.

No human trial has shown the blend will do any of this, and a 2024 test suggests the TB-500 fragment may not even be its own active piece. What's there is two coherent mechanisms, a consistent signal across dozens of animal studies for each compound, and a mild reported side-effect profile. It's worth being curious about. It isn't enough to rely on, and it won't replace the basics that actually have evidence behind them: rest, rehab, sleep, and loading the tissue properly.

How to reconstitute Wolverine

A 20 mg 1:1 vial (10 mg each) mixed with 2 mL bacteriostatic water gives 5 mg/mL each, so 5 units draws 250 mcg of both.

The vial arrives as a small puck of dry powder holding both peptides already combined. Before you can use it, you mix it into a liquid. That step is called reconstitution, and it's the same process used for BPC-157 and TB-500 on their own. The only difference is that one draw now carries a dose of each.

Step 1Start with powderWipe the rubber stopper with an alcohol swab.

Step 2Add bac. waterRun it slowly down the inside wall — never shake.

Step 3Draw your doseThe calculator gives the exact units to draw to.

Wipe the rubber stopper with an alcohol swab first, every time.
Use bacteriostatic water, not plain sterile water and not saline. The trace of benzyl alcohol in it holds back bacteria, which matters because you'll be drawing from the same vial for weeks.
Add the water slowly, running it down the inside glass wall. Don't blast it straight onto the powder.
Don't shake it. Swirl gently and let it dissolve on its own. Shaking foams the solution and can damage the peptides.

One commonly sold format is a 20 mg blend vial holding 10 mg BPC-157 and 10 mg TB-500 in a 1:1 ratio. Mixed with 2 mL of bacteriostatic water, that gives 10 mg/mL total, which is 5 mg/mL of each peptide. On a U-100 insulin syringe, 5 units then draws 250 mcg of each, and 10 units draws 500 mcg of each. Other formats and ratios are sold, so confirm your vial's numbers before you do the math. Because the two are blended in a fixed ratio, you can't dose them independently; every draw moves both together. The water doesn't change how much peptide is in the vial, only the concentration, which decides how many units you draw.

Calculate your exact Wolverine reconstitution →

Dose & units

No dose is FDA-approved; reports cluster at 250-500 mcg of each peptide once daily, run 6-12 weeks on then off, dosed as one fixed unit.

There is no FDA-approved dose for either compound, so there's none for the blend. Everything below is a range that clinics and write-ups report, not a medical standard. Because the two peptides come in a fixed ratio, you dose the blend as a unit and can't tune one without moving the other. Decide what goes into your body with a licensed provider, not with this page.

Typical range

For a 1:1 blend, reports cluster around 250–500 mcg of each peptide per day, drawn together once daily. That lands in the usual BPC-157 range while keeping TB-500 lower than its standalone milligram-per-week protocols, which is a real tradeoff of the fixed ratio rather than a sign one dose is correct.

Titration

Most people start near the low end, around 250 mcg of each for the first week or two, and adjust from there. Starting low lets you notice any reaction before you've committed to more. There's no medal for starting high.

Cycling

Reports treat this as a time-limited course, commonly 6–12 weeks on, then several weeks off before repeating. Some run a heavier front-loaded stretch and then taper, mirroring TB-500's load-then-maintain pattern. The spread itself tells you how soft these numbers are.

On6–12 weeks

Offseveral weeks

For the exact mark to draw to on your insulin syringe, don't eyeball it. The calculator turns your vial size, water, and dose into the precise number of units, and accounts for both peptides in the blend.

Get your exact units →

Storage

Sealed powder keeps for months at room temperature; once mixed, refrigerate at 2-8 C and use within about four weeks.

Sealed & dryDry, unmixed vial stays stable for months at room temperature and tolerates shipping heat.

ReconstitutedRefrigerate at 2-8 C in the main compartment, use within about 4 weeks, never freeze, and discard if cloudy.

You'll see longer windows quoted for peptide vials. Those figures are beyond-use dates for a sealed, unmixed vial that a compounding pharmacy has stability-tested, and they stop applying the moment you add water. A mixed vial runs on the roughly four-week clock instead, because that's how long the preservative in bacteriostatic water reliably keeps the solution clean once you're drawing from it.

That four-week limit is about contamination, not potency. The peptides themselves often stay good well beyond it. Reconstitute with plain sterile water instead of bacteriostatic and you drop to a day or two, since there's no preservative holding bacteria back.

Don't freeze a reconstituted vial, keep it out of direct light, write the mix date on the label, and throw it out if the solution ever turns cloudy or discolored, whatever the date says.

Side effects & safety

Reported effects are mild injection-site and early-cycle reactions, but stacking two compounds doubles the odds and both promote blood-vessel growth, a real concern with any cancer history.

The reported side effects of each compound are generally mild, and the blend's profile is just the two combined. That picture comes from animal studies and scattered clinic and user reports, not large human safety trials, so hold it loosely.

Most common: mild, short-lived redness or irritation right at the injection site.
Less often: some swelling at the site, mild nausea, brief fatigue, or a light-headed feeling in the first few days of a cycle.
Stacking two compounds means twice the chance of an individual reaction, even if each is mild on its own.

Talk to a doctor before you start if you have a history of cancer. Both compounds promote new blood-vessel growth, and TB-500 also drives cell migration. The same effects that might help healing could, in theory, also feed tissue you don't want growing, and you're stacking two of them. That's unproven, but worth taking seriously. The same goes if you're pregnant, breastfeeding, or managing a serious health condition.

If you compete, both compounds are banned by WADA. BPC-157 has been listed under S0 (non-approved substances) since 2022; TB-500, as thymosin beta-4 and its fragments, has been prohibited since 2011, both in and out of competition. Running the blend means carrying both bans at once, and a positive test for either is a doping violation. On the regulatory side, the FDA removed several peptides including these two from the 503A Category 2 list in April 2026 and scheduled a compounding review for July 2026, but neither is FDA-approved, and that doesn't change the WADA status.

And the biggest risk here isn't really the molecules. It's whether the vial actually contains both peptides, at the strengths on the label. With a blend that's two ways to get shorted in one bottle, and you can't see it in the powder. That comes down to where you buy it.

How to vet a source

A blend doubles the risk, so demand a batch-specific, third-party COA confirming both BPC-157 and TB-500 are present at the stated amounts, with the lot number matching your vial.

A blend doubles the sourcing problem. This is an unregulated market where a real share of independently tested vials come back underdosed, impure, or not even the compound on the label, and here a seller has to get two peptides right, at the right ratio, in one vial. A certificate of analysis matters more, not less: it should confirm both BPC-157 and TB-500 are present, identified, and at the stated amounts. That's a third-party lab's report on what's actually in the vial.

A real COA shows

An identity test (usually mass spectrometry) confirming the peptide is what the label says.
A purity figure from HPLC, typically 98% or higher.
A lot or batch number that matches the number printed on your vial.
A named, independent accredited lab and a recent test date.

Walk away if

There’s no COA, or it’s a generic image with no lot number.
The “certificate” comes from the seller instead of a third-party lab.
The lot number doesn’t match your vial, or there isn’t one at all.
It’s a flat image you can’t trace back to the lab that issued it.

That's the standard worth holding any seller to, ours included. With a blend, ask that the batch-specific COA cover both peptides, match the lot number to your vial, and don't accept a screenshot in place of a traceable report.

See the Zapify compound catalog →

Common questions about Wolverine

Is Wolverine a single peptide?

No. It's a blend of two separate peptides, BPC-157 and TB-500, premixed in one vial, often at a 1:1 ratio though sellers vary. The name is a community label borrowed from the fast-healing comic character, not a clinical or chemical designation. Each compound has its own guide, and the blend inherits everything true of both.

Is the Wolverine blend approved or proven to work in people?

No. Neither BPC-157 nor TB-500 is FDA-approved, so the blend isn't either, and no published trial has tested the combination in humans. The evidence is the separate animal and cell-culture research on each compound. The FDA removed both from the 503A Category 2 list in April 2026 and scheduled a compounding review for July 2026, but that's a regulatory process, not approval or proof of efficacy.

Why run BPC-157 and TB-500 together instead of one?

The argument is that they cover different parts of repair. BPC-157's animal research leans toward local tissue, tendon, ligament, and gut, while TB-500 leans toward cell migration and flexibility across muscle and connective tissue. People stack them hoping the local and systemic mechanisms add up. That synergy is untested in humans; it's the rationale, not a proven result.

Can I dose the two peptides separately in a blend?

Not in a premixed vial. The two come in a fixed ratio, so every draw delivers both at once and you can't tune one without moving the other. If you want independent control, for instance BPC-157 in micrograms a day and TB-500 in milligrams a week, run them as separate vials instead of a blend.

Is the Wolverine blend banned in sport?

Yes, doubly. BPC-157 has been on the WADA list under S0 since 2022, and TB-500, as thymosin beta-4 and its fragments, has been prohibited since 2011, both in and out of competition. Running the blend means carrying both bans, and a positive test for either is a doping violation. The 2026 FDA compounding changes don't affect WADA status.

References

This page is for research and educational purposes only. It is not medical advice or a recommendation to use any compound. The dose ranges shown are reported by clinics and research literature, not validated medical standards, and Wolverine is not FDA-approved. Talk to a licensed medical provider about anything you put in your body.